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SUMMARY 
Chronic treatment of rats with the antipsychotic drugs haloperidol and (+)-butaclamol 
results in supersensitivity of striatal dopamine (DA) recepers. Striatal membranes of 
these animals have an increased content of an endogenous Ca -binding protein, calmodulin. 
Both endogenous and protein kinase-induced release of calmodulin from striatal membranes 
of the antipsychotic drug-treated animals were found substantially lower than that from 
saline or (-)-butaclamol-treated rats. Acute treatment with the antipsychotic drugs pro- 
duced no alterations in calmodulin content or calmodulin release from the membranes. The 
impaired calmodulin release seen in the chronic antipsychotic drug-treated rats could be 
associated with the supersensitivity of DA receptors. 
INTRODUCTION 
Ca 
++ THE CYCLIC nucleotide concentration in the brain can be modulated by the endogenous 
-binding protein, calmodulin. In the brain, this protein can stimulate both soluble 
cyclic nucleotide phosphodiesterase activity (Cheung, 1971) and membrane-bound adenylate 
cyclase activity (Brostrom, Huang, Breckenridge and Wolff, 1975). In this tissue, calmodu- 
lin is mostly located in the membrane portion of the cell and can be released from this 
fraction into the cytosol by phosphorylation of a membrane binding site (Gnegy, Costa and 
Uzunov, 1976a). Release of calmodulin from striatal membranes reduces the activation of 
adenylate cyclase by dopamine (DA) (Gnegy. Uzunov and Costa, 1976b). The calmodulin content 
was increased in the striatal membranes of rats treated chronically with cataleptogenic 
antipsychotic drugs that produce behavioral supersensitivity to apomorphine (Gnegy, Lucchelli 
and Costa, 1977a; Gnegy, Uaunov and Costa, 1977b). Moreover, the striatal membranes from 
these animals had increased basal and DA-sensitive adenylate cyclase activity. A reduction 
in calmodulin release could lead to its accumulation in the membrane, which in turn could 
contribute to the greater adenylatecyclase activity and dopaminergic supersensitivity. There- 
fore, the purpose of this study was to examine whether calmodulin release from the striatal 
membranes is altered in rats treated chronically with antipsychotic drugs. Calmodulin re- 
lease was also measured after acute treatment with the drugs which does not result in be- 
havioral supersensitivity to DA. 
METHODS 
Male, Sprague Dawley rats (150-2OOg) were injected daily for 20 days with either halo- 
peridol, (+)-butaclamol, (-)-butaclamol (all at 2.5 pmol/kg s.c.) or saline. One week 
after the end of treatment some of the animals (N=8) were tested for behavioral supersensi- 
tivity to a single dose of apomorphine HCl (1.9 pmol/kg s.c.) as described previously 
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(Gnegy et al., 1977a,b). In accordance with previous results, animals chronically treated 
with haloperidol and (+)-butaclamol showed greater stereotyped behavior to apomorphine than 
those treated with saline or (-)-butaclamol. 
Animals not used in behavioral studies were sacrificed by decapitation. The striata 
were removed, homogenized in 9 vol of 0.32M sucrose and then spun at 20,000 x g for 30 min. 
The membrane pellets were resuspended in 50 mM Pipes (piperazine-N,N'-bis [2_ethanesulfonic 
acid]) buffer, pH 7.0. Calmodulin release was measured in an assay containing, in a final 
volume of 100 81: 50 mM Pipes buffer, pH 7.0, 10 mM magnesium chloride, 5 ug of partially 
purified membrane-derived protein kinase from bovine brain (Uno, Ueda and Greengard, 1977), 
go-100 pg of striatal membrane protein and 25 I.~M ATP. The reaction was carried out for 
5 min at 30°C and was stopped by plunging the tubes into ice and centrifuging them immedi- 
ately at 20,000 x g for 30 min. An aliquot of the supernatant was heated at 95°C for 1 
min and the calmodulin content was determined using the phosphodiesterase assay as described 
previously (Gnegy et al., 1976a). The calmodulin content in the particulate fraction 
(containing 0.5-2 ug protein) of the striatum was similarly determined, except the membrane 
was tnitially solublized in 1% Lubrol PX. The calmodulin content was measured in nanograms 
using a standard curve obtained with highly purified calmodulin prepared from bovine brain 
(Klee, 1977). Protein was measured by the method of Lowry, Rosenbrough, Farr and Randall 
(1951), using bovine serum albumin as a standard. 
RESULTS AND DISCUSSION 
The release of calmodulin from the striatal membranes of rats treated chronically with 
haloperidol, (+)-butaclamol, (-)-butaclamol or saline was measured. As Figure 1 shows 
there was a substantial endogenous release of ca~moduli~fr~ the striatal membranes of 
saline-treated rats that occurred in the presence of Mg and ATP. The addition of 5 lig 
of membrane-derived protein kinase elicited a further release of calmodulin. The calmodu- 
lin release using striatal membranes from the haloperidol-treated rats was very different 
from that of control animals. In this case the endogenous calmodulin release was sharply 
decreased to only 30% of the control value. Calmodulin can be further released by protein 
kinase in the membranes of haloperidol-treated rats but not to control levels. 
The results obtained using rats which were chronically treated with (+)-butaclamol 
are very similar to those of the haloperidol-treated rats (Figure 2). The endogenous re- 
lease from striatal membranes of (-)-butaclamol-treated rats was markedly less (44% decrease) 
than that from saline controls. The amount of calmodulin released upon addition of exoge- 
nous protein kinase was also lower than the control value (Figure 2). The endogenous re- 
lease and protein kinase stimulated release from the membranes of (+)-butaclamol-treated 
animals were also significantly different from that of the (-)-butaclamol-treated animals. 
On the other hand, in all respects the values for (-)-butaclamol were similar to control 
values. 




Figure 1. Calmodulin release from striatal membranes of rats treated chronically with sa- 
line and haloperidol. Animals were injected daily for 20 days with haloperidol (2.5 nmol/ 
kg s.c.) or saline. One week after stopping chronic injections the rats were sacrificed 
and calmodulin release was measured as described in Methods.PK=5 ug of protein kinase in 
the assay. Bars represent mean values for 8 rats f S.E.M. *p < 0.001 when compared with 
saline-treated rats. 
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Figure 2. Calmodulin release from striatal membranes of rats treated chronically with sa- 
line, (+)-butaclamol and (-)-butaclamol. Animals were injected daily for 20 days with (+)- 
butaclamol, (-)-butaclsmol (2.5 umol/kg s.c.) or saline. One week after stopping chronic 
injections the rats were sacrificed and calmodulin release was measured as described in 
Methods. PK=5ug of protein kinase in the assay. Bars represent mean values f S.E.M. The 
number of animals is given in parenthesis. *p < 0.01 with respect to saline-treated con- 
trols and (-)-butaclamol-treated rats. **p < 0.05 with respect to saline-treated controls 
and (-)-butaclamol-treated rats. 
The reduction in calmodulin release from striatal membranes of supersensitive rats is 
not simply due to a lack of calmodulin in the membranes. The haloperidol-treated animals 
had a 28% increase in their striatal membrane content of calmodulin(5.lf 0.1 ng/ug protein 
in haloperidol-treated animals, 4.0 It 0.2 ng/ug protein in saline-treated rats, p < 0.01, 
N=8). Therefore, the percentage of calmodulin that could be released from the membranes of 
haloperidol-treated rats ‘(9%) was nearly three-fold less than that from membranes of con- 
trol rats (24%), (N=8). 
Calmodulin release after acute treatment with a single dose of haloperidol, (+)-buta- 
clamol, (-)-butaclamol (all at 2.5 umol/kg s.c.) or saline was also studied. The animals 
were sacrificed one hour after the drug treatment. At the time of sacrifice, the haloperi- 
dol-treated and (+)-butaclamol-treated rats exhibited stuporous behavior which was not seen 
in the (-)-butaclamol or saline-treated animals. 
The release of calmodulin from the striatal membrane of animals acutely treated with 
haloperidol and (+)-butaclamol was not different from that of saline or (-)-butaclamol- 
treated rats (Table 1). Furthermore, there was no significant change in membrane calmodu- 
lin content of the acutely drug-treated rats as compared to the saline controls. (Table 
1). 
As demonstrated in this study, rats treated chronically with haloperidol and (+)-buta- 
clam01 showed a decreased calmodulin release from that of saline of (-)-butaclamol controls. 
Furthermore, acute treatment of rats with the drugs haloperidol, (+)-, or (-)-butaclamol 
produced no change in striatal calmodulin content or its release from membranes. An im- 
paired ability to release calmodulin in these chronic antipsychotic drug-treated animals 
could lead to its eventual accumulation in the membrane. This latter phenomenon could 
cause an increase in DA-sensitive adenylate cyclase activity (Gnegy et al., 1977a,b), which 
would contribute to the dopaminergic supersensitivity in the striatum produced by chronic 
DA receptor blockade. 
The greatest difference between the drug-treated and control groups was in the endoge- 
nous calmodulin release. The mechanism of this endogenous release isunknownat the pre- 
sent time. Prel#nary observations, however, suggst that this endogenous release is 
regulated by a Ca -dependent process, possibly Ca -dependent protein kinase activity. 
Since the primary function of calmodulin is to bind calcium, it is logical that the calcium 
concentration itself could be a modulator of the binding and "releasability" of calmodulin. 
The significant decrease in endogenous release of calmodulin in the supersensitive animals 
could reflect a.change in calcium concentration or sequestration in the membranes of these 
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TABLE 1 
Calmodulin content and its release from striatal membranes of rats acutely 
treated with saline, haloperidol, (+)-butaclamol, and (-)-butaclamol 
Membrane Calmodulin Calmodulin release from membrane 
Treatment N Content -protein kinase +protein kinase 
ng calmodulin/ug membrane protein + S.E.M. _ 
Expt. I 
Saline 6 3.7 f 0.3 1.2 f 0.1 1.6 + 0.1" 
Haloperidol 8 4.0 + 0.2 1.2 + 0.1 1.8 ;t O.l* 
Expt. II 
Saline 4 3.8 + 0.4 1.2 ? 0.1 1.9 + 0.1* 
(+)-Butaclamol 8 3.4 + 0.3 1.1 f 0.1 2.0 + 0.1* 
(-)-Butaclamol 8 3.9 f 0.2 1.2 * 0.1 1.9 + 0.1* 
Animals were given one injection of haloperidol, (+)-butaclamol, (-)-butaclamol (2.5 umol/ 
s.c.) or saline. The animals were sacrificed one hour after treatment and the calmodulin 
release was measured as described in METHODS. *The increase in release by protein kinase 
is significant at p < 0.05. All values among the treatments are not statistically differ- 
ent. 
animals. Exogenously added protein kinase did not release the calmodulin from the mem- 
branes of the chronic antipsychotic drug-treated rats to the same levels as those seen 
in the saline-treated controls. Since we are adding an adequate amount of protein kinase 
in the assay, this indicates that perhaps some of the substrate for the reaction in the 
former groups is present in a less reactive state. 
The results from this study are important because they can begin to explain intermem- 
brane molecular events that occur during supersensitivity to the neurotransmitter, DA. 
Supersensitivity and subsensitivity of catecholamine-linked adenylate cyclase could be due 
to many factors and be exhibited at many levels such as the receptor, catalytic activity 
of adenylate cyclase, any intermembrane "linking" factors (such as GTP-binding proteins or 
calmodulin) between receptor and cyclase, or phosphodiesterase and protein kinase activity. 
All of these factors have been shown to be involved in various examples of supersensitivity 
and subsensitivity to catecholamines (see review by Gnegy and Costa, 1980). 
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